Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder

Purpose: The aim of the present study was to define gene expression profiles of noninvasive and invasive bladder cancer, to identify potential therapeutic or screening targets in bladder cancer, and to define genetic changes relevant for tumor progression of recurrent papillary bladder cancer (pTa). Experimental Design: Overall, 67 bladder neoplasms (46 pTa, 3 pTis, 10 pT1, and 8 pT2) and eight normal bladder specimens were investigated by a combination of laser microdissection and gene expression profiling. Eight of 16 patients with recurrent noninvasive papillary bladder tumors developed carcinoma in situ (pTis) or invasive bladder cancer (≥pT1G2) in the course of time. RNA expression results of the putative progression marker cathepsin E (CTSE) were confirmed by immunohistochemistry using high-throughput tissue microarray analysis (n = 776). Univariate analysis of factors regarding overall survival, progression-free survival, and recurrence-free survival in patients with urothelial bladder cancer was done. Results: Hierarchical cluster analyses revealed no differences between pTaG1 and pTaG2 tumors. However, distinct groups of invasive cancers with different gene expression profiles in papillary and solid tumors were found. Progression-associated gene profiles could be defined (e.g., FABP4 and CTSE) and were already present in the preceding noninvasive papillary tumors. CTSE expression (P = 0.003) and a high Ki-67 labeling index of at least 5% (P = 0.01) were the only factors that correlated significantly with progression-free survival of pTa tumors in our gene expression approach. Conclusions: Gene expression profiling revealed novel genes with potential clinical utility to select patients that are more likely to develop aggressive disease.

[1]  S. Groshen,et al.  Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. , 1998, Cancer research.

[2]  T. H. van der Kwast,et al.  The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.

[3]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[4]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[5]  Holger Moch,et al.  Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade , 2001, The Journal of pathology.

[6]  L. Kiemeney,et al.  Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. , 1993, The Journal of urology.

[7]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[8]  L. Dyrskjøt.  Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics , 2003, Expert review of molecular diagnostics.

[9]  Y. Kawahito,et al.  Expression of peroxisome proliferator‐activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists , 2003, International journal of cancer.

[10]  Torben F. Ørntoft,et al.  Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-invasive and Invasive Human Transitional Cell Carcinomas* , 2002, Molecular & Cellular Proteomics.

[11]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[12]  M. Parmar,et al.  Can p53 staining be used to identify patients with aggressive superficial bladder cancer? , 2003, Journal of Pathology.

[13]  T. H. van der Kwast,et al.  Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Richie,et al.  Biology and management of bladder cancer. , 1990, The New England journal of medicine.

[15]  R. Knuechel,et al.  Laser Microdissection and Microsatellite Analyses of Breast Cancer Reveal a High Degree of Tumor Heterogeneity , 2001, Pathobiology (Basel).

[16]  Wentian Li,et al.  Copyright © American Society for Investigative Pathology Gene Discovery in Bladder Cancer Progression using cDNA Microarrays , 2022 .

[17]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[18]  C. Pilarsky,et al.  Gene expression profiles of microdissected pancreatic ductal adenocarcinoma , 2003, Virchows Archiv.

[19]  I. Gromova,et al.  Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas. , 1998, International journal of oncology.

[20]  M. Kruhøffer,et al.  Identification of gene expression patterns in superficial and invasive human bladder cancer. , 2001, Cancer research.

[21]  B. Chain,et al.  Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation. , 2000, Seminars in Cell and Developmental Biology.

[22]  K. Matsuo,et al.  Immunohistochemical localization of cathepsins D and E in human gastric cancer: a possible correlation with local invasive and metastatic activities of carcinoma cells. , 1996, Human pathology.

[23]  R Y Ball,et al.  Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs , 2005 .

[24]  G. Sauter,et al.  HER‐2 and TOP2A coamplification in urinary bladder cancer , 2003, International journal of cancer.

[25]  C. Pilarsky,et al.  Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues. , 1999, Nucleic acids research.

[26]  O. Dalesio,et al.  Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. , 1983, The Journal of urology.

[27]  J. Celis,et al.  Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. , 1996, Cancer research.

[28]  A. Regev,et al.  Molecular analysis of transitional cell carcinoma using cDNA microarray , 2003, Oncogene.

[29]  Toshiyuki Sakai,et al.  Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma , 2000, Journal of gastroenterology and hepatology.

[30]  C. Cordon-Cardo,et al.  Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. , 1997, Cancer research.

[31]  M. Tatematsu,et al.  Immunohistochemically demonstrated variation in expression of cathepsin E between uracil-induced papillomatosis and N-butyl-N-(4-hydroxybutyl)nitrosamine-induced preneoplastic and neoplastic changes in rat urinary bladder , 1996, Virchows Archiv.

[32]  N. Socci,et al.  Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. , 2002, Cancer research.

[33]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[34]  X. Yi,et al.  Monitoring gene expression profile changes in bladder transitional cell carcinoma using cDNA microarray. , 2002, Urologic oncology.

[35]  C. Tinelli,et al.  Aspartic proteinases in normal lung and interstitial pulmonary diseases. , 1993, American journal of respiratory cell and molecular biology.

[36]  Peng Liu,et al.  Selective Cooperation between Fatty Acid Binding Proteins and Peroxisome Proliferator-Activated Receptors in Regulating Transcription , 2002, Molecular and Cellular Biology.

[37]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[38]  Rolf Ackermann,et al.  Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder , 2004, Clinical Cancer Research.

[39]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[40]  F. Mostofi,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. , 1998, The American journal of surgical pathology.

[41]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[42]  F. Marincola,et al.  High-fidelity mRNA amplification for gene profiling , 2000, Nature Biotechnology.

[43]  J. Kay,et al.  Slow moving proteinase. Isolation, characterization, and immunohistochemical localization in gastric mucosa. , 1987, Gastroenterology.

[44]  R. Zappatore,et al.  Cervical adenocarcinomas express markers common to gastric, intestinal, and pancreatobiliary epithelial cells. , 1994, Pathology, research and practice.

[45]  John Quackenbush,et al.  Genesis: cluster analysis of microarray data , 2002, Bioinform..

[46]  J. Kay,et al.  Slow moving proteinase , 1987 .

[47]  H. Nakanishi,et al.  New Functional Aspects of Cathepsin D and Cathepsin E , 2000, Molecules and cells.

[48]  A. Smith,et al.  Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. , 1989, Biochemistry.

[49]  A. Althausen,et al.  Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. , 1976, The Journal of urology.

[50]  J. Southgate,et al.  Expression of cytokeratin 20 redefines urothelial papillomas of the bladder , 1999, The Lancet.

[51]  R. Sylvester,et al.  Prognostic factors in superficial bladder tumors , 1992 .

[52]  S. Shousha,et al.  Immunohistochemical identification of tumours of adipocytic differentiation using an antibody to aP2 protein. , 1995, Journal of clinical pathology.

[53]  P. Hamilton,et al.  The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  Mogens Kruhøffer,et al.  Gene Expression in the Urinary Bladder , 2004, Cancer Research.